2024
Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse eventsShorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention
Park D, Hu J, Jamil Y, Kelsey M, Jones W, Frampton J, Kochar A, Aronow W, Damluji A, Nanna M. Shorter Dual Antiplatelet Therapy for Older Adults After Percutaneous Coronary Intervention. JAMA Network Open 2024, 7: e244000. PMID: 38546647, PMCID: PMC10979312, DOI: 10.1001/jamanetworkopen.2024.4000.Peer-Reviewed Original ResearchConceptsOlder adultsMonths of DAPTDuration of dual antiplatelet therapySystematic reviewRandomized clinical trialsPercutaneous coronary interventionMeta-analysisPreferred Reporting ItemsAssess data qualityRisk of bleedingDuration of DAPTDual antiplatelet therapyWeb of ScienceMain OutcomesReporting ItemsData extractionAbstracted dataSecondary outcomesRisk ratioAntiplatelet therapyPrimary outcomeCochrane LibraryCoronary interventionReference groupNetwork meta-analysis
2023
Chronological comparison of TAVI and SAVR stratified to surgical risk: a systematic review, meta-analysis, and meta-regression
Park D, An S, Kassab K, Jolly N, Attanasio S, Sawaqed R, Malhotra S, Doukky R, Vij A. Chronological comparison of TAVI and SAVR stratified to surgical risk: a systematic review, meta-analysis, and meta-regression. Acta Cardiologica 2023, 78: 778-789. PMID: 37294002, DOI: 10.1080/00015385.2023.2218025.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve implantationAll-cause mortalitySevere aortic regurgitationSevere paravalvular regurgitationSurgical riskAortic regurgitationPacemaker placementParavalvular regurgitationFollow-upAlternative to surgical aortic valve replacementAssociated with higher all-cause mortalityLong-term follow-upNewer-generation valvesRisk of all-cause mortalityPeriod of follow-upHigh surgical riskIntermediate surgical riskLow surgical riskMeta-regressionAortic valve replacementSevere aortic stenosisMeta-analysisLong-term outcomesScore-matched studyFactor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis
Park D, An S, Kumar A, Malhotra S, Jolly N, Kaur A, Kattoor A, Doukky R, Kalra A, Vij A. Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis. American Journal Of Cardiovascular Drugs 2022, 22: 633-645. PMID: 35781867, DOI: 10.1007/s40256-022-00541-w.Peer-Reviewed Original ResearchConceptsNet adverse clinical eventsDuration of DAPTPercutaneous coronary interventionNetwork meta-analysisShorter duration of DAPTStent thrombosisMyocardial infarctionDrug-eluting stentsMeta-analysisResultsSeventeen randomized controlled trialsSystematic reviewAdverse cardiac eventsAdverse clinical eventsFrequentist network meta-analysesRisk of myocardial infarctionBackgroundDual antiplatelet therapyMonths of DAPTRandomized controlled trialsRandom-effects modelNetwork meta-analysesClinical presentationNo significant differenceAntiplatelet therapyMethodsThe present studyCardiac eventsFactor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis
Park D, An S, Arif A, Vij A. Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2022, 40: 82-83. DOI: 10.1016/j.carrev.2022.06.184.Peer-Reviewed Original ResearchSystematic Review and Network Meta‐Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention
Park D, An S, Jolly N, Attanasio S, Yadav N, Rao S, Vij A. Systematic Review and Network Meta‐Analysis Comparing Bifurcation Techniques for Percutaneous Coronary Intervention. Journal Of The American Heart Association 2022, 11: e025394. PMID: 35723005, PMCID: PMC9238651, DOI: 10.1161/jaha.122.025394.Peer-Reviewed Original ResearchAdverse cardiac eventsTarget lesion revascularizationTarget vessel revascularizationRandomized clinical trialsCardiac eventsPercutaneous coronary interventionCardiac deathLesion revascularizationConventional meta-analysisVessel revascularizationStent thrombosisMyocardial infarctionMeta-analysisRelative riskProvisional stentingClinical trialsHigher rates of restenosisAssociated with lower procedural successCoronary interventionAssociated with lower riskPooled relative riskBayesian network meta-analysesFrequentist network meta-analysisAll-cause mortalityLower procedural successCRT-500.16 Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis
Park D, An S, Arif A, Vij A. CRT-500.16 Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis. JACC Cardiovascular Interventions 2022, 15: s49. DOI: 10.1016/j.jcin.2022.01.203.Peer-Reviewed Original Research